Your browser doesn't support javascript.
loading
Asprosin and meteorin-like protein immunoreactivity in invasive ductal breast carcinoma stages.
Akkus, Gulsum; Koyuturk, Leyla Canpolat; Yilmaz, Mustafa; Hancer, Serhat; Ozercan, Ibrahim Hanifi; Kuloglu, Tuncay.
Afiliação
  • Akkus G; Firat University, Medical School, Department of Histology and Embriyology, Elazig, Turkey. Electronic address: akgulsum76@gmail.com.
  • Koyuturk LC; Firat University, Medical School, Department of Histology and Embriyology, Elazig, Turkey. Electronic address: lcan@firat.edu.tr.
  • Yilmaz M; Firat University, Medical School, Department of Emergency Medicine, Elazig, Turkey. Electronic address: drmylmz@hotmail.com.
  • Hancer S; Firat University, Medical School, Department of Histology and Embriyology, Elazig, Turkey. Electronic address: serhathancer87@gmail.com.
  • Ozercan IH; Firat University, Medical School, Department of Pathology, Elazig, Turkey. Electronic address: ozercanih@hotmail.com.
  • Kuloglu T; Firat University, Medical School, Department of Histology and Embriyology, Elazig, Turkey. Electronic address: tkuloglu@firat.edu.tr.
Tissue Cell ; 77: 101855, 2022 Aug.
Article em En | MEDLINE | ID: mdl-35749857
ABSTRACT

AIM:

The study aimed to investigate asprosin (ASP) and meteorin-like (METRNL) protein immunoreactivity in invasive ductal breast cancer. MATERIALS AND

METHODS:

Overall, 60 cases of invasive ductal breast cancer (20 cases each of Grade 1, 2 and 3) were evaluated in addition to 20 normal breast tissues obtained from the Pathology Department Archive. ASP and METRNL expressions were assessed using immunohistochemical staining and visualised under a light microscope.

RESULTS:

There was a significant difference in ASP and METRNL immunoreactivity among all the groups included in the study (p < 0.001). Cancer tissues with Grade 1, 2 and 3 showed a significant increase in ASP and METRNL immunoreactivity compared with the control group; however, no significant difference was noted among the cancer tissues with Grade 1, 2 and 3.

CONCLUSIONS:

ASP and METRNL immunoreactivity increased at the cellular level in invasive ductal breast cancer, but there was no difference in immunoreactivity among the breast cancer grades.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama Limite: Female / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama Limite: Female / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article